Past President Argentine Lipid Society. Internal Medicine physician and Lipidologist. Pharmacology Professor at FASTA University, School of Medicine.
🤔Do Triglyceride‐Rich Lipoproteins (TRL) Equal Low‐Density Lipoproteins (LDL) in Risk of ASCVD? 👉 Current consensus is moving towards recognizing remnant cholesterol and LDL cholesterols as equals per 1 mmol/L (39 mg/dL) higher levels in the risk assessment of ASCVD; hence, triglyceride-rich lipoprotein-lowering therapies should also lower levels of non-HDL cholesterol to reduce ASCVD risk https://lnkd.in/diz4PhkD European Atherosclerosis Society Børge Nordestgaard
Global Business Development | Export Manager at Zeta Pharma | In & Out Licensing | B2B Pharmaceuticals ُExpert | Driving International Sales Growth in Emerging Markets in Africa, GCC and CIS Regions
11moGood